Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Ependymoblastoma is a rare type of primitive neuroectodermal tumor (PNET) that usually occurs in young children under the age of 2 and is histologically distinguished by the production of ependymoblastic rosettes. It is associated with an aggressive course and a poor prognosis.
Biomarker and diagnostic research for ependymoblastoma has been reported in the published literature.
13 clinical trials registered, 12 recruiting. Interventions under study include drug therapy, biologic therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE2, 9 PHASE1, 1 EARLY_PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03911388](https://clinicaltrials.gov/study/NCT03911388) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors |
PHASE1 |
M.D. Anderson Cancer Center |
RECRUITING |
[NCT06861244](https://clinicaltrials.gov/study/NCT06861244) | Embryonal Tumor With Multilayered Rosettes | PHASE2 | University of California, San Francisco | RECRUITING |
[NCT07087002](https://clinicaltrials.gov/study/NCT07087002) | GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults | PHASE1 | Stanford University | RECRUITING |
[NCT06465199](https://clinicaltrials.gov/study/NCT06465199) | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | PHASE1 | Milton S. Hershey Medical Center | RECRUITING |
[NCT06193759](https://clinicaltrials.gov/study/NCT06193759) | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) | PHASE1 | Children's National Research Institute | RECRUITING |
144 publications have been identified in PubMed for ependymoblastoma. Research spans Basic Science / Preclinical (44%), Gene Therapy / Novel Therapeutics (16%), and Clinical Trial Publication (12%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 63 | 44% |
New treatment approaches | 23 | 16% |
Clinical study results | 17 | 12% |
Research summaries | 12 | 8% |
Testing and diagnosis research | 11 | 8% |
Patient case studies | 10 | 7% |
Disease patterns and progression | 8 | 6% |
Oztek MA (2026). [PMID: 41274772](https://pubmed.ncbi.nlm.nih.gov/41274772/). *Neuroimaging clinics of North America*. [Review / Meta-Analysis]
Radke K (2026). [PMID: 41437160](https://pubmed.ncbi.nlm.nih.gov/41437160/). *EMBO molecular medicine*. [Gene Therapy / Novel Therapeutics]
Min HK (2026). [PMID: 40897897](https://pubmed.ncbi.nlm.nih.gov/40897897/). *Nat Biomed Eng*. [Basic Science / Preclinical]
Totaro S (2026). [PMID: 41502392](https://pubmed.ncbi.nlm.nih.gov/41502392/). *Dis Model Mech*. [Basic Science / Preclinical]
Werr L (2026). [PMID: 41678281](https://pubmed.ncbi.nlm.nih.gov/41678281/). *J Clin Invest*. [Gene Therapy / Novel Therapeutics]
Poverennaya I (2026). [PMID: 41803115](https://pubmed.ncbi.nlm.nih.gov/41803115/). *Nat Commun*. [Basic Science / Preclinical]
Zhou H (2026). [PMID: 41213462](https://pubmed.ncbi.nlm.nih.gov/41213462/). *Cancer Lett*. [Basic Science / Preclinical]
Conces MR (2026). [PMID: 41612478](https://pubmed.ncbi.nlm.nih.gov/41612478/). *Diagnostic pathology*. [Basic Science / Preclinical]
Kumaria A (2026). [PMID: 40794235](https://pubmed.ncbi.nlm.nih.gov/40794235/). *Brain tumor pathology*. [Diagnostic / Biomarker]
Tauziède-Espariat A (2026). [PMID: 41817752](https://pubmed.ncbi.nlm.nih.gov/41817752/). *Virchows Archiv : an international journal of pathology*. [Gene Therapy / Novel Therapeutics]